Gefitinib was proved to be effective in the treatment of hormone resistant and hormone receptor negative advanced breast cancer in the phase II clinical trial (Polychronis et al., 2005; Green et al., 2009). This evidence concerns the gene NR4A1 and breast carcinoma.